BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. [PMID: 16009685 DOI: 10.1136/gut.2004.049460] [Cited by in Crossref: 549] [Cited by in F6Publishing: 477] [Article Influence: 34.3] [Reference Citation Analysis]
Number Citing Articles
1 Sonavane AD, Sonawane P, Amarapurkar DN. Inflammatory Bowel Disease Across the Age Continuum: Similarity and Disparity. Indian J Pediatr. 2018;85:989-994. [PMID: 29572605 DOI: 10.1007/s12098-018-2665-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
2 Haddad A, Ben Mahmoud A, Maghrebi H, Chelly B, Jouini M, Kacem MJ. Management of an uncommon T-Cell lymphoma revealed by an anastomotic dehiscence in Crohn's disease: A case report. Int J Surg Case Rep 2021;79:53-7. [PMID: 33429357 DOI: 10.1016/j.ijscr.2021.01.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Korelitz BI, Reddy B, Bratcher J. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2010;9:379-82. [PMID: 20367524 DOI: 10.1517/14740330903571626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
4 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). Intest Res 2018;16:178-93. [PMID: 29743831 DOI: 10.5217/ir.2018.16.2.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
5 Shyn PB. 18F-FDG positron emission tomography: potential utility in the assessment of Crohn’s disease. Abdom Imaging. 2012;37:377-386. [PMID: 21833729 DOI: 10.1007/s00261-011-9793-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
6 Otto F, Neuen-Jacob E, Arendt G, Stüve O, Hartung HP. A 69-year-old man with left hemispheric necrotizing mass lesion. Brain Pathol 2009;19:541-4. [PMID: 19563549 DOI: 10.1111/j.1750-3639.2009.00304.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
8 Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2021;15:840-59. [PMID: 32915970 DOI: 10.1093/ecco-jcc/jjaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Moyer AM. NUDT15: A bench to bedside success story. Clin Biochem 2021;92:1-8. [PMID: 33675810 DOI: 10.1016/j.clinbiochem.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105. [PMID: 23032984 DOI: 10.1038/ajg.2012.334] [Cited by in Crossref: 142] [Cited by in F6Publishing: 120] [Article Influence: 15.8] [Reference Citation Analysis]
11 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 2016;17:1339-49. [DOI: 10.1080/14656566.2016.1187132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Goessling W, Mayer RJ. Systemic Treatment of Patients Who Have Colorectal Cancer and Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:713-27. [DOI: 10.1016/j.gtc.2006.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
13 Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80-85. [PMID: 18849016 DOI: 10.1016/j.cgh.2008.08.028] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 8.8] [Reference Citation Analysis]
14 Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LAAP, Groenen PJTA, van Krieken JHJM, Hoentjen F. Epstein–Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. Journal of Crohn's and Colitis 2015;9:398-403. [DOI: 10.1093/ecco-jcc/jjv040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
15 Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. Am J Gastroenterol 2017;112:1135-43. [PMID: 28534520 DOI: 10.1038/ajg.2017.96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
16 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 486] [Article Influence: 80.1] [Reference Citation Analysis]
17 Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;CD000067. [PMID: 26517527 DOI: 10.1002/14651858.cd000067.pub3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
18 Nakano M, Tominaga K, Hoshino A, Sugaya T, Kanke K, Hiraishi H. Therapeutic efficacy of an elemental diet for patients with crohn's disease and its association with amino acid metabolism. Saudi J Gastroenterol 2017;23:20-7. [PMID: 28139496 DOI: 10.4103/1319-3767.199110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
20 Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009;22:418-30. [PMID: 19845719 DOI: 10.1111/j.1529-8019.2009.01258.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
21 Rosh JR. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:302-7. [DOI: 10.1007/s11894-008-0060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464-78.e1-5. [PMID: 24267475 DOI: 10.1053/j.gastro.2013.10.046] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 13.1] [Reference Citation Analysis]
23 Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769-79. [PMID: 17628557 DOI: 10.1053/j.gastro.2007.04.075] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 9.4] [Reference Citation Analysis]
24 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
25 Sonu IS, Blonski W, Lin MV, Lewis J, Aberra F, Lichtenstein GR. Papillary thyroid cancer and inflammatory bowel disease: Is there a relationship? World J Gastroenterol 2013; 19(7): 1079-1084 [PMID: 23467027 DOI: 10.3748/wjg.v19.i7.1079] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, Joyce JC, Katsanos KH, Lopez A, de Xaxars TM, Toader E, Beaugerie L. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8:31-44. [PMID: 23721759 DOI: 10.1016/j.crohns.2013.04.006] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
27 Kempinska A, Benchimol EI, Mack A, Barkey J, Boland M, Mack DR. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr 2011;53:389-93. [PMID: 21681112 DOI: 10.1097/MPG.0b013e31822855e7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
28 Korelitz BI. Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. World J Gastroenterol 2013; 19(20): 2979-2984 [PMID: 23716977 DOI: 10.3748/wjg.v19.i20.2979] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
29 Levi Z, Fraser E, Krongrad R, Hazazi R, benjaminov O, meyerovitch J, Tal OB, Choen A, Niv Y, Fraser G. Factors associated with radiation exposure in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:1128-1136. [PMID: 19899197 DOI: 10.1111/j.1365-2036.2009.04140.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
30 Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sørensen HT, Baron JA. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265-73.e1. [PMID: 23602821 DOI: 10.1016/j.cgh.2013.03.034] [Cited by in Crossref: 112] [Cited by in F6Publishing: 97] [Article Influence: 14.0] [Reference Citation Analysis]
31 Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol. 2009;104:2566-2571. [PMID: 19550415 DOI: 10.1038/ajg.2009.372] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
32 Denby KS, Beck LA. Update on systemic therapies for atopic dermatitis. Current Opinion in Allergy & Clinical Immunology 2012;12:421-6. [DOI: 10.1097/aci.0b013e3283551da5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
33 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
34 Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:453-60. [PMID: 28129288 DOI: 10.1097/MIB.0000000000001021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 9.7] [Reference Citation Analysis]
35 Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces? Semin Cancer Biol. 2014;24:61-70. [PMID: 24333759 DOI: 10.1016/j.semcancer.2013.12.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 13.5] [Reference Citation Analysis]
36 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
37 Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017;318:1679-86. [PMID: 29114832 DOI: 10.1001/jama.2017.16071] [Cited by in Crossref: 229] [Cited by in F6Publishing: 192] [Article Influence: 57.3] [Reference Citation Analysis]
38 Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis. 2007;13:896-902. [PMID: 17345605 DOI: 10.1002/ibd.20131] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
39 Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. BMJ. 2006;333:340-343. [PMID: 16902215 DOI: 10.1136/bmj.333.7563.340] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
40 Dohan A, Faraoun S, Barral M, Guerrache Y, Boudiaf M, Dray X, Hoeffel C, Allez M, Farges O, Beaugerie L, Aparicio T, Marteau P, Fishman E, Lucidarme O, Eveno C, Pocard M, Dautry R, Soyer P. Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. Diagnostic and Interventional Imaging 2015;96:871-83. [DOI: 10.1016/j.diii.2015.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tran V, Limketkai BN, Sauk JS. IBD in the Elderly: Management Challenges and Therapeutic Considerations. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0720-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, Annese V, D'albasio G, Manes G, Travis S, Porro GB, Ardizzone S. Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. Am J Gastroenterol 2009;104:2760-7. [DOI: 10.1038/ajg.2009.410] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 6.8] [Reference Citation Analysis]
43 Cesarini M, Festa S, Papi C. Methotrexate in Crohn’s disease: a new face for an old drug? Expert Review of Gastroenterology & Hepatology 2016;10:1135-44. [DOI: 10.1080/17474124.2016.1185363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
44 McGurgan IJ, McGuigan C. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. Brain Behav 2015;5:e00396. [PMID: 26516615 DOI: 10.1002/brb3.396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
45 Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2:39-47. [PMID: 17722511 DOI: 10.2147/nano.2007.2.1.39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
46 Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion 2007;76:161-8. [PMID: 18239408 DOI: 10.1159/000111031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
47 Allen PB, Laing G, Connolly A, O’Neill C. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem? BMJ Case Rep. 2013;2013:pii: bcr2013200423. [PMID: 24081592 DOI: 10.1136/bcr-2013-200423] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
48 Korelitz BI, Present DH. 6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn’s disease. J Crohns Colitis. 2014;8:735-738. [PMID: 24462321 DOI: 10.1016/j.crohns.2013.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
49 Kayton ML. Cancer and pediatric inflammatory bowel disease. Semin Pediatr Surg. 2007;16:205-213. [PMID: 17602977 DOI: 10.1053/j.sempedsurg.2007.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Lichtenstein GR. Medical Management of Crohn's Disease in 2006: What's on the Horizon? Am J Gastroenterology 2007;102:S2-6. [DOI: 10.1111/j.1572-0241.2007.01291.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
52 Zhou JQ, Zeng L, Zhang Q, Wu XY, Zhang ML, Jing XT, Wang YF, Gan HT. Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi J Gastroenterol 2020. [PMID: 33078719 DOI: 10.4103/sjg.SJG_30_20] [Reference Citation Analysis]
53 DʼHaens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, Arikan D, Perotti E, Robinson AM, Kalabic J, Alperovich G, Thakkar R, Loftus EV. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol 2018;113:872-82. [PMID: 29867173 DOI: 10.1038/s41395-018-0098-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
54 Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187-208. [PMID: 17328579 DOI: 10.2165/00003088-200746030-00001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 99] [Article Influence: 8.3] [Reference Citation Analysis]
55 Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:525-41. [PMID: 25110257 DOI: 10.1016/j.gtc.2014.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
56 Papanastasiou L, Pappa T, Tsiavos V, Tseniklidi E, Androulakis I, Kontogeorgos G, Piaditis G. Azathioprine as an alternative treatment in primary hypophysitis. Pituitary 2011;14:16-22. [DOI: 10.1007/s11102-010-0252-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
57 McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883-898. [PMID: 23046232 DOI: 10.2217/imt.12.85] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
58 Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835-1842, quiz 1843. [PMID: 24042192 DOI: 10.1038/ajg.2013.294] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
59 Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428-1435; quiz 1436. [PMID: 18494836 DOI: 10.1111/j.1572-0241.2008.01836.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
60 Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012;27:385-389. [PMID: 21793904 DOI: 10.1111/j.1440-1746.2011.06865.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
61 Parian A, Lazarev M. Who and how to screen for cancer in at-risk inflammatory bowel disease patients. Expert Rev Gastroenterol Hepatol 2015;9:731-46. [PMID: 25592672 DOI: 10.1586/17474124.2015.1003208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
62 Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. Inflamm Bowel Dis 2015;21:1847-53. [PMID: 25993693 DOI: 10.1097/MIB.0000000000000457] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 9.6] [Reference Citation Analysis]
63 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613. [PMID: 18564323 DOI: 10.1111/j.1365-2036.2008.03772.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
64 Biancone L, Armuzzi A, Scribano ML, D’inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; on behalf of the Italian Group for the study of Inflammatory Bowel Disease. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. ECCOJC 2016;10:913-24. [DOI: 10.1093/ecco-jcc/jjw048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
65 Wielenga MC, Jeude JFVL, Rosekrans SL, Levin AD, Schukking M, D’Haens GR, Heijmans J, Jansen M, Muncan V, Brink GRVD. Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis. World J Gastroenterol 2014; 20(44): 16683-16689 [PMID: 25469037 DOI: 10.3748/wjg.v20.i44.16683] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Scharl S, Barthel C, Rossel JB, Biedermann L, Misselwitz B, Schoepfer AM, Straumann A, Vavricka SR, Rogler G, Scharl M, Greuter T. Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study. Am J Gastroenterol 2019;114:116-26. [PMID: 30333538 DOI: 10.1038/s41395-018-0360-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
67 Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 2015; 6(4): 181-192 [PMID: 26600976 DOI: 10.4291/wjgp.v6.i4.181] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
68 Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4:511-522. [PMID: 21122554 DOI: 10.1016/j.crohns.2010.05.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 6.5] [Reference Citation Analysis]
69 Mclaughlin PD, Maher MM. Nonneoplastic Diseases of the Small Intestine: Differential Diagnosis and Crohn Disease. American Journal of Roentgenology 2013;201:W174-82. [DOI: 10.2214/ajr.12.8495] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
70 Tao F, Qian C, Guo W, Luo Q, Xu Q, Sun Y. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. Biochem Pharmacol 2013;85:798-807. [PMID: 23261528 DOI: 10.1016/j.bcp.2012.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
71 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 164] [Article Influence: 61.3] [Reference Citation Analysis]
72 Devlin SM, Cheifetz AS, Siegel CA. Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2012;41:411-28. [DOI: 10.1016/j.gtc.2012.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
73 Chatu S, Subramanian V, Pollok RC. Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:529-539. [PMID: 22239831 DOI: 10.1111/j.1365-2036.2011.04975.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
74 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
75 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711-734. [PMID: 21950502 DOI: 10.1111/j.1365-2133.2011.10575.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 8.4] [Reference Citation Analysis]
76 Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2015;21:2948-57. [DOI: 10.1097/mib.0000000000000631] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
78 Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis. 2008;40 Suppl 2:S247-S252. [PMID: 18598996 DOI: 10.1016/s1590-8658(08)60533-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
79 Kannengiesser K, Maaser C, Kucharzik T. Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. Per Med 2008;5:609-26. [PMID: 29788621 DOI: 10.2217/17410541.5.6.609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
81 Sondheimer JM. Lymphoma After Imuran and 6-MP: A New Look. Journal of Pediatric Gastroenterology & Nutrition 2005;41:683-4. [DOI: 10.1097/01.mpg.0000184430.41625.e0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007;26:987-1003. [PMID: 17877506 DOI: 10.1111/j.1365-2036.2007.03455.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
83 Mckeon A. Immunotherapeutics for Autoimmune Encephalopathies and Dementias. Curr Treat Options Neurol 2013;15:723-37. [DOI: 10.1007/s11940-013-0251-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
84 Benkov K, Lu Y, Patel A, Rahhal R, Russell G, Teitelbaum J. Role of Thiopurine Metabolite Testing and Thiopurine Methyltransferase Determination in Pediatric IBD. Journal of Pediatric Gastroenterology & Nutrition 2013;56:333-40. [DOI: 10.1097/mpg.0b013e3182844705] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
85 Cao L. Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis. World J Surg Oncol 2018;16:182. [PMID: 30200972 DOI: 10.1186/s12957-018-1485-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
86 Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients: Review: communicating risks of IBD therapy. Alimentary Pharmacology & Therapeutics 2011;33:23-32. [DOI: 10.1111/j.1365-2036.2010.04489.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
87 Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012;83:283-292. [PMID: 22047938 DOI: 10.1016/j.critrevonc.2011.10.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
88 Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391-399.e1. [PMID: 22155755 DOI: 10.1016/j.cgh.2011.11.026] [Cited by in Crossref: 168] [Cited by in F6Publishing: 122] [Article Influence: 16.8] [Reference Citation Analysis]
89 Phillips F, Verstockt B, Ribaldone DG, Guerra I, Teich N, Katsanos K, Filip R, Molnar T, Karmiris K. Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER case series. J Crohns Colitis 2021:jjab164. [PMID: 34508639 DOI: 10.1093/ecco-jcc/jjab164] [Reference Citation Analysis]
90 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
91 Levesque BG, Loftus EV. Medical Management of Ulcerative Colitis: Conventional Therapy—Azathioprine. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 413-9. [DOI: 10.1007/978-3-319-33703-6_40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Kansal S, Wagner J, Kirkwood CD, Catto-Smith AG. Enteral nutrition in Crohn's disease: an underused therapy. Gastroenterol Res Pract 2013;2013:482108. [PMID: 24382954 DOI: 10.1155/2013/482108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
93 Sands BE, Siegel CA. Crohn's Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1941-1973.e9. [DOI: 10.1016/b978-1-4160-6189-2.00111-6] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
94 Bremner A, Beattie R. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opinion on Pharmacotherapy 2007;8:2553-68. [DOI: 10.1517/14656566.8.15.2553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
95 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
96 Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855. [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
97 Bewtra M, Lewis JD. Safety Profile of IBD: Lymphoma Risks. Medical Clinics of North America 2010;94:93-113. [DOI: 10.1016/j.mcna.2009.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;9:177-89. [DOI: 10.1586/17474124.2014.945914] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
99 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
100 Zenouzi R, Weismüller TJ, Jørgensen KK, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen TH, Boberg KM, Manns MP, Lohse AW, Schramm C. No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 2016;14:1806-12. [DOI: 10.1016/j.cgh.2016.07.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
101 McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chernyukhin N, Blosch C, Zack DJ. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18. [PMID: 20546618 DOI: 10.1186/1546-0096-8-18] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
102 Brambilla M, De Mauri A, Leva L, Carriero A, Picano E. Cumulative radiation dose from medical imaging in chronic adult patients. Am J Med 2013;126:480-6. [PMID: 23541374 DOI: 10.1016/j.amjmed.2012.10.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
103 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
104 Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90. [PMID: 23749336 DOI: 10.1007/s40259-013-0045-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
105 Blonski W, Buchner AM, Lichtenstein GR. Treatment of ulcerative colitis. Curr Opin Gastroenterol. 2014;30:84-96. [PMID: 24285003 DOI: 10.1097/mog.0000000000000031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
106 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C, Baggi F, Cornelio F, Durelli L, Clerico M, Piccolo G, Cosi V. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009;256:1221-7. [DOI: 10.1007/s00415-009-5091-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
108 Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48:1405-1413. [PMID: 24131389 DOI: 10.3109/00365521.2013.846402] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
109 Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. J Gastroenterol Hepatol 2018;33:1485-91. [PMID: 29406567 DOI: 10.1111/jgh.14116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
110 Kalman RS, Hartshorn K, Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015;21:428-35. [PMID: 25251059 DOI: 10.1097/MIB.0000000000000211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
111 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14(36): 5523-5527 [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
112 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
113 Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594. [PMID: 24479980 DOI: 10.1111/apt.12639] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 17.9] [Reference Citation Analysis]
114 El-Nachef N, Terdiman J, Mahadevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010;105:1210-1211. [PMID: 20445523 DOI: 10.1038/ajg.2010.33] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
115 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
116 Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis. 2010;16:2109-2116. [PMID: 20848473 DOI: 10.1002/ibd.21290] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
117 Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update. J Intern Med 2008;264:514-27. [PMID: 19017176 DOI: 10.1111/j.1365-2796.2008.02029.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
118 Velayos F. Managing risks of neoplasia in inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:174-180. [PMID: 22359106 DOI: 10.1007/s11894-012-0247-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
119 Guo J, Jin H, Shi Z, Yin J, Pasricha T, Chen JDZ. Sacral nerve stimulation improves colonic inflammation mediated by autonomic-inflammatory cytokine mechanism in rats. Neurogastroenterol Motil 2019;31:e13676. [PMID: 31327175 DOI: 10.1111/nmo.13676] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
120 Grossi V, Hyams JS. The safety of treatment options for pediatric Crohn’s disease. Expert Opinion on Drug Safety 2016;15:1383-90. [DOI: 10.1080/14740338.2016.1203418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
121 Dimitroulis D, Patsouras D, Katsargyris A, Charalampoudis P, Anastasiou I, Kouraklis G. Primary enteric-type mucinous adenocarcinoma of the urethra in a patient with ulcerative colitis. Int Surg. 2014;99:669-672. [PMID: 25216440 DOI: 10.1159/000282492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
122 Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis 2014;20:103-14. [PMID: 24280881 DOI: 10.1097/01.MIB.0000437498.14804.50] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
123 Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;CD000478. [PMID: 22972046 DOI: 10.1002/14651858.cd000478.pub3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
124 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881. [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 313] [Article Influence: 28.8] [Reference Citation Analysis]
125 Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk. 2010;10:144-148. [PMID: 20371449 DOI: 10.3816/clml.2010.n.021] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
126 Rojas-Feria M, Eslam M, Castro-Fernández M, Guerrero P, Larraona-Moreno JL, Romero-Gómez M. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 2011;5:608-11. [PMID: 22115382 DOI: 10.1016/j.crohns.2011.04.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
127 Nussinson E, Shibli F, Shahbari A, Rock W, Elias M, Elmalah I. Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease. World J Gastroenterol 2014; 20(3): 857-862 [PMID: 24574759 DOI: 10.3748/wjg.v20.i3.857] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
128 Bousvaros A, Morley-Fletcher A, Pensabene L, Cucchiara S. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis. 2008;40:32-38. [PMID: 17996504 DOI: 10.1016/j.dld.2007.07.168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
129 de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:686-94. [DOI: 10.1038/ncpgasthep1000] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 6.0] [Reference Citation Analysis]
130 Matters GL, Harms JF, Mcgovern C, Fitzpatrick L, Parikh A, Nilo N, Smith JP. The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease. Journal of Immunotoxicology 2008;5:179-87. [DOI: 10.1080/15476910802131469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
131 Kaulen LD, Karschnia P, Dietrich J, Baehring JM. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 2020;149:153-9. [PMID: 32683530 DOI: 10.1007/s11060-020-03583-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
132 Rogler G, Sandborn WJ. Is there still a role for thiopurines in Crohn's disease? Gastroenterology 2013;145:714-6. [PMID: 23973853 DOI: 10.1053/j.gastro.2013.08.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
133 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:433-6. [DOI: 10.1038/nrgastro.2009.87] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
135 Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063-2071. [PMID: 22271569 DOI: 10.1002/ibd.22889] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
136 Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1283-1293. [PMID: 17059510 DOI: 10.1111/j.1365-2036.2006.03126.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
137 Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;CD006320. [PMID: 24585498 DOI: 10.1002/14651858.cd006320.pub4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
138 Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009;38:669-89. [PMID: 19913208 DOI: 10.1016/j.gtc.2009.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
139 Bae SI, Kim YS. Colon cancer screening and surveillance in inflammatory bowel disease. Clin Endosc. 2014;47:509-515. [PMID: 25505716 DOI: 10.5946/ce.2014.47.6.509] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
140 Destombe S, Bouron-DalSoglio D, Rougemont AL, Fournet JC, Ovetchkine P, Champagne J, Deslandres C. Lymphomatoid granulomatosis: a unique complication of Crohn disease and its treatment in pediatrics. J Pediatr Gastroenterol Nutr 2010;50:559-61. [PMID: 20639715 DOI: 10.1097/MPG.0b013e3181b64586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
141 Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015;21:445-452. [PMID: 25248004 DOI: 10.1097/mib.0000000000000197] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
142 Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res 2018;16:194-208. [PMID: 29743832 DOI: 10.5217/ir.2018.16.2.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
143 Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [PMID: 26168366 DOI: 10.7326/M14-0960] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
144 Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci 2018;18:211-6. [PMID: 29338679 DOI: 10.17305/bjbms.2018.2792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
145 Siegmund B, Preiss JC, Zeitz M. [What has been confirmed in the treatment of inflammatory bowel disease?]. Internist (Berl) 2010;51:1492-8. [PMID: 21069274 DOI: 10.1007/s00108-010-2719-x] [Reference Citation Analysis]
146 Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 2014;15:1659-70. [DOI: 10.1517/14656566.2014.925445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
147 Mazzola G, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infect. 2017;74:433-441. [PMID: 28263759 DOI: 10.1016/j.jinf.2017.02.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
148 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
149 Aardoom MA, Joosse ME, de Vries ACH, Levine A, de Ridder L. Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis 2018;24:732-41. [PMID: 29522170 DOI: 10.1093/ibd/izx104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
150 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
151 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
152 Moffatt D, Bernstein CN. State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. In: Cohen RD, editor. Inflammatory Bowel Disease. Totowa: Humana Press; 2011. pp. 93-110. [DOI: 10.1007/978-1-60327-433-3_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
153 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212-223. [PMID: 24394749 DOI: 10.1038/ajg.2013.441] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 17.9] [Reference Citation Analysis]
154 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31-42. [PMID: 21180588 DOI: 10.1177/1756283x09354136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
156 Vos AC, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, Stokkers P, van Bodegraven AA, Pierik M, van der Woude CJ, Oldenburg B, Hommes DW. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study: . Inflammatory Bowel Diseases 2011;17:1837-45. [DOI: 10.1002/ibd.21582] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
157 Carchman E. Crohn's Disease and the Risk of Cancer. Clin Colon Rectal Surg 2019;32:305-13. [PMID: 31275078 DOI: 10.1055/s-0039-1683923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Maira González N, Scocco S, Estepa R. [Hodgkin's lymphoma associated with inflammatory bowel disease treated with thiopurines. A case report and review of the literature]. Rev Esp Patol 2019;52:242-5. [PMID: 31530407 DOI: 10.1016/j.patol.2018.11.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 D'haens G, Rutgeerts P. Immunosuppression-associated lymphoma in IBD. The Lancet 2009;374:1572-3. [DOI: 10.1016/s0140-6736(09)61487-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
160 Zenker S, Neurath MF, Atreya I. Targeted inhibition of Vav1 activity does not favour development of colitis-associated colon cancer. Inflamm Bowel Dis. 2013;19:E72-E73. [PMID: 23435399 DOI: 10.1097/mib.0b013e31827eeabe] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther 2017;45:50-62. [PMID: 27883215 DOI: 10.1111/apt.13838] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
162 Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14(3): 378-389 [PMID: 18200660 DOI: 10.3748/wjg.14.378] [Cited by in CrossRef: 204] [Cited by in F6Publishing: 188] [Article Influence: 15.7] [Reference Citation Analysis]
163 Bewtra M. Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. American Journal of Gastroenterology 2012;107:964-70. [DOI: 10.1038/ajg.2011.479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
164 Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5512-5518 [PMID: 18810768 DOI: 10.3748/wjg.14.5512] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
165 Saito S, Shimizu U, Nan Z, Mandai N, Yokoyama J, Terajima K, Akazawa K. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. J Crohns Colitis 2013;7:167-74. [PMID: 22626508 DOI: 10.1016/j.crohns.2012.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
166 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
167 Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol. 2018;74:5-16. [PMID: 29337025 DOI: 10.1016/j.humpath.2018.01.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
168 Burger DC, Florin THJ. Hepatosplenic T‐cell lymphoma following infliximab therapy for Crohn's disease. Medical Journal of Australia 2009;190:341-2. [DOI: 10.5694/j.1326-5377.2009.tb02435.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
169 Suzuki T, Iwamoto K, Nozaki R, Saiki Y, Tanaka M, Fukunaga M, Yamada K. Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report. BMC Surg 2021;21:50. [PMID: 33478454 DOI: 10.1186/s12893-021-01060-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
171 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
172 Wei X, Zhang L, Zhang R, Wu R, Si D, Ahmad B, Petitte JN, Mozdziak PE, Li Z, Guo H, Zhang M. A highly efficient hybrid peptide ameliorates intestinal inflammation and mucosal barrier damage by neutralizing lipopolysaccharides and antagonizing the lipopolysaccharide-receptor interaction. FASEB J 2020;34:16049-72. [PMID: 33058296 DOI: 10.1096/fj.201903263RRR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Stallmach A, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. J Crohns Colitis. 2011;5:177-188. [PMID: 21575879 DOI: 10.1016/j.crohns.2011.02.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
174 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
175 Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459-77. [PMID: 24405149 DOI: 10.1111/apt.12616] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 13.9] [Reference Citation Analysis]
176 Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
177 Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:511-516. [PMID: 17980127 DOI: 10.1157/13111681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
178 Shukla T, Jin J, Marginean EC, Saloojee N. Anaplastic large cell lymphoma of the colon in a patient with colonic Crohn disease treated with infliximab and methotrexate. Can J Gastroenterol Hepatol 2014;28:11-2. [PMID: 24416734 DOI: 10.1155/2014/687592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
179 Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Review of Clinical Immunology 2014;6:659-66. [DOI: 10.1586/eci.10.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
180 Severyns T, Kirchgesner J, Lambert J, Thieblemont C, Amiot A, Abitbol V, Treton X, Cazals-Hatem D, Malamut G, Coppo P, Galicier L, Walter-Petrich A, Deau-Fischer B, Besson C, Aparicio T, Beaugerie L, Allez M, Gornet JM. Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. J Crohns Colitis 2020;14:1222-30. [PMID: 32161943 DOI: 10.1093/ecco-jcc/jjaa048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
181 Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21-28. [PMID: 17200426 DOI: 10.1345/aph.1h219] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
182 Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM. Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease. Am J Gastroenterology 2007;102:2804-12. [DOI: 10.1111/j.1572-0241.2007.01474.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
183 Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis 2020;26:450-9. [PMID: 31498388 DOI: 10.1093/ibd/izz155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
184 Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24-30. [PMID: 23094824 DOI: 10.1111/jgh.12015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
185 Koronakis N, Lagoudianakis E, Keramidaris D, Pappas A, Gemenetzis G, Seretis C, Chrysikos J, Manouras A. Mesentery lymphoma in a patient with Crohn’s disease: An extremely rare entity. Int J Surg Case Rep. 2012;3:343-345. [PMID: 22580080 DOI: 10.1016/j.ijscr.2012.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
186 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
187 Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220-227. [PMID: 17988235 DOI: 10.1111/j.1365-2036.2007.03570.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
188 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
189 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 879] [Article Influence: 89.2] [Reference Citation Analysis]
190 Blonski W, Lichtenstein GR. Safety of biologic therapy: . Inflammatory Bowel Diseases 2007;13:769-96. [DOI: 10.1002/ibd.20027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
191 Kobayashi T, Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. J Crohns Colitis 2020;14:617-23. [PMID: 31867632 DOI: 10.1093/ecco-jcc/jjz204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
192 Yang C, Huang J, Huang X, Huang S, Cheng J, Liao W, Chen X, Wang X, Dai S. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:1042-52. [PMID: 29762681 DOI: 10.1093/ecco-jcc/jjy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
193 Dotimas J, Das M, Martin D. Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review. SAGE Open Med Case Rep 2020;8:2050313X20937223. [PMID: 32655868 DOI: 10.1177/2050313X20937223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
194 Yadlapati S, Efthimiou P. Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk? Biomed Res Int 2016;2016:8631061. [PMID: 27429984 DOI: 10.1155/2016/8631061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
195 Scribano ML. Adverse events of IBD therapies: . Inflammatory Bowel Diseases 2008;14:S210-1. [DOI: 10.1097/00054725-200810001-00099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
196 Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2008;2:105-124. [PMID: 19072374 DOI: 10.1586/17474124.2.1.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
197 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
198 Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OS, Munkholm P. Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark: . Inflammatory Bowel Diseases 2007;13:481-9. [DOI: 10.1002/ibd.20036] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 19.2] [Reference Citation Analysis]
199 Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205-211. [PMID: 16534422 DOI: 10.1097/01.mib.0000217770.21261.ce] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
200 Newnham E, Hawkes E, Surender A, James SL, Gearry R, Gibson PR. Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? Aliment Pharmacol Ther. 2007;26:1019-1024. [PMID: 17877508 DOI: 10.1111/j.1365-2036.2007.03449.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
201 Rodriguez AA, Kerner J, Luna-Fineman S, Berry GJ. Hodgkin lymphoma following adalimumab for the treatment of Crohn’s disease in an adolescent. Dig Dis Sci. 2014;59:2403-2405. [PMID: 24817339 DOI: 10.1007/s10620-014-3191-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
202 Erkan G, Coban M, Calıskan A, Ataç GK, Gulpınar K, Degertekin B, Korkmaz A. A Burkitt's Lymphoma Case Mimicking Crohn's Disease: A Case Report. Case Rep Med 2011;2011:685273. [PMID: 21912555 DOI: 10.1155/2011/685273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
203 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
204 Ding Y, Liang Y, Deng B, Qiao A, Wu K, Xiao W, Gong W. Induction of TGF-β and IL-10 production in dendritic cells using astilbin to inhibit dextran sulfate sodium-induced colitis. Biochem Biophys Res Commun. 2014;446:529-534. [PMID: 24613838 DOI: 10.1016/j.bbrc.2014.02.136] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
205 Mossop H, Davies P, Murphy MS. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2008;47:123-9. [PMID: 18664861 DOI: 10.1097/MPG.0b013e318156a834] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
206 Nuti F, Civitelli F, Cucchiara S. Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases. Pediatr Drugs 2014;16:343-52. [DOI: 10.1007/s40272-014-0084-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
207 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
208 Stan MS, Voicu SN, Caruntu S, Nica IC, Olah NK, Burtescu R, Balta C, Rosu M, Herman H, Hermenean A, Dinischiotu A. Antioxidant and Anti-Inflammatory Properties of a Thuja occidentalis Mother Tincture for the Treatment of Ulcerative Colitis. Antioxidants (Basel) 2019;8:E416. [PMID: 31546840 DOI: 10.3390/antiox8090416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
209 Martín De Carpi J, Varea V. Respuesta a la suspensión de azatioprina en pacientes con enfermedad de Crohn en terapia combinada con infliximab. Anales de Pediatría 2009;70:271-7. [DOI: 10.1016/j.anpedi.2008.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
210 Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447. [PMID: 18848556 DOI: 10.1053/j.gastro.2008.09.053] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
211 Chandan JS, Thomas T. The impact of inflammatory bowel disease on oral health. Br Dent J 2017;222:549-53. [PMID: 28387295 DOI: 10.1038/sj.bdj.2017.318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
212 Vodopivec I, Matiello M, Prasad S. Treatment of neuromyelitis optica. Curr Opin Ophthalmol 2015;26:476-83. [PMID: 26367088 DOI: 10.1097/ICU.0000000000000202] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
213 Atia O, Ledder O, Ben-moshe T, Lev-tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. Journal of Pediatric Gastroenterology & Nutrition 2020;70:825-32. [DOI: 10.1097/mpg.0000000000002566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
214 Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;CD006443. [PMID: 17636844 DOI: 10.1002/14651858.cd006443.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 0.7] [Reference Citation Analysis]
215 Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
216 Leung Y, Hanauer S. Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together? Gastroentérologie Clinique et Biologique 2009;33:S202-8. [DOI: 10.1016/s0399-8320(09)73155-0] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
217 Friedman S. Cancer in Crohn’s disease. Gastroenterol Clin North Am. 2006;35:621-639. [PMID: 16952744 DOI: 10.1016/j.gtc.2006.07.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
218 Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. Am J Gastroenterol 2009;104:2524-33. [DOI: 10.1038/ajg.2009.322] [Cited by in Crossref: 136] [Cited by in F6Publishing: 119] [Article Influence: 11.3] [Reference Citation Analysis]
219 Zabana Y, Garcia-planella E, van Domselaar M, Mañosa M, Gordillo J, López-sanromán A, Cabré E, Domènech E. Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. Gastroenterología y Hepatología 2013;36:616-23. [DOI: 10.1016/j.gastrohep.2013.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
220 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 514] [Article Influence: 50.5] [Reference Citation Analysis]
221 Van Hauwaert V, Meers S, Verhoef G, Tousseyn T, Sagaert X, Vermeire S, Rutgeerts P, Van Assche G. Rectal non-Hodgkin‘s lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis. 2010;4:683-686. [PMID: 21122582 DOI: 10.1016/j.crohns.2010.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
222 Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101-112. [PMID: 19258190 DOI: 10.1016/j.bpg.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
223 Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3146-3152 [PMID: 24696600 DOI: 10.3748/wjg.v20.i12.3146] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
224 Hashash JG, Abo S, Regueiro M. An unusual cause of lower gastrointestinal bleeding in Crohn's disease. Malignant infiltration with Epstein-Barr virus-positive diffuse large B-cell non-Hodgkin's lymphoma. Gastroenterology. 2012;142:1421, 1623. [PMID: 22543110 DOI: 10.1053/j.gastro.2011.12.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;:CD000478. [PMID: 17253451 DOI: 10.1002/14651858.CD000478.pub2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
226 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
227 Ahmad OF, Keane MG, McCartney S, Khwaja A, Bloom SL. Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis. Frontline Gastroenterol 2013;4:205-9. [PMID: 28839727 DOI: 10.1136/flgastro-2012-100276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Pozadzides JV, Pro B. Hepatosplenic T-cell lymphoma and TNF-α inhibitors. Expert Rev Hematol 2009;2:611-4. [PMID: 21082951 DOI: 10.1586/ehm.09.62] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
229 Katz S. “Mind the Gap”: An Unmet Need for New Therapy in IBD. Journal of Clinical Gastroenterology 2007;41:799-809. [DOI: 10.1097/mcg.0b013e318033d71d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
230 Harris RE, Hegde V, Curtis L, Garrick V, Gervais L, Armstrong L, Delahunty C, Eccleston A, Al-Hourani G, Flynn DM, Merrick V, Barclay AR, Tayler R, Hansen R, Russell RK. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J Pediatr Gastroenterol Nutr 2021;73:358-62. [PMID: 34091548 DOI: 10.1097/MPG.0000000000003197] [Reference Citation Analysis]
231 Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. Dig Dis Sci 2019;64:60-7. [PMID: 30311154 DOI: 10.1007/s10620-018-5322-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
232 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 10.6] [Reference Citation Analysis]
233 Mourad AP, De Robles MS, Winn RD. Intestinal T-cell lymphoma presenting as colonic perforation in the setting of ulcerative colitis: a case report. Clin J Gastroenterol 2021;14:176-80. [PMID: 33174156 DOI: 10.1007/s12328-020-01279-1] [Reference Citation Analysis]
234 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
235 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
236 Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012] [Cited by in Crossref: 647] [Cited by in F6Publishing: 585] [Article Influence: 49.8] [Reference Citation Analysis]
237 Bourikas L, Tzardi M, Hatzidakis A, Koutroubakis I. Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. Digestive and Liver Disease 2008;40:144. [DOI: 10.1016/j.dld.2007.08.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
238 Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM; GJCF-CC&BR. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord 2012;1:180-7. [PMID: 24555176 DOI: 10.1016/j.msard.2012.06.002] [Cited by in Crossref: 154] [Cited by in F6Publishing: 136] [Article Influence: 17.1] [Reference Citation Analysis]
239 Gaca AM, Jaffe TA, Delaney S, Yoshizumi T, Toncheva G, Nguyen G, Frush DP. Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatr Radiol 2008;38:285-91. [PMID: 18183380 DOI: 10.1007/s00247-007-0702-z] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
240 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
241 Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30 Suppl 3:55-66. [PMID: 23295693 DOI: 10.1159/000342603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
242 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
243 Reynolds GJ, Annis KA, de Villiers WJ. Review article: multiple myeloma and inflammatory bowel disease. Dig Dis Sci 2007;52:2022-8. [PMID: 17420948 DOI: 10.1007/s10620-006-9165-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
244 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
245 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
246 Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007;:CD006320. [PMID: 17443620 DOI: 10.1002/14651858.CD006320.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
247 Ahn SM, Suh SO, Oh YM, Yun CY, Sim HH, Park CA, Song CM, Bae JY. [A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine]. Korean J Gastroenterol 2013;62:248-52. [PMID: 24162714 DOI: 10.4166/kjg.2013.62.4.248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
248 Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study. J Crohns Colitis 2017;11:954-62. [PMID: 28333358 DOI: 10.1093/ecco-jcc/jjx040] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
249 Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Reference Citation Analysis]
250 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
251 Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology. 2017;152:1901-1914.e3. [PMID: 28193515 DOI: 10.1053/j.gastro.2017.02.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 28.5] [Reference Citation Analysis]
252 Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-8. [PMID: 19828563 DOI: 10.1136/ard.2009.117762] [Cited by in Crossref: 137] [Cited by in F6Publishing: 114] [Article Influence: 11.4] [Reference Citation Analysis]
253 Hagen JW, Pugliano-Mauro MA. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg 2018;44:469-80. [PMID: 29315147 DOI: 10.1097/DSS.0000000000001455] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 9.3] [Reference Citation Analysis]
254 Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010;105:1604-1609. [PMID: 20104215 DOI: 10.1038/ajg.2009.745] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 9.3] [Reference Citation Analysis]
255 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 28.2] [Reference Citation Analysis]
256 Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, Straub G, Meyer R, Kamenisch Y, Berneburg M. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant. 2012;12:218-225. [PMID: 21943390 DOI: 10.1111/j.1600-6143.2011.03751.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
257 Chan EP, Lichtenstein GR. Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:675-712. [DOI: 10.1016/j.gtc.2006.07.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
258 van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased. Clinical Gastroenterology and Hepatology 2011;9:449-450.e1. [DOI: 10.1016/j.cgh.2011.01.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
259 Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-954. [PMID: 19086165 DOI: 10.1080/00365520801957149] [Cited by in Crossref: 194] [Cited by in F6Publishing: 176] [Article Influence: 16.2] [Reference Citation Analysis]
260 Bargalló A, Carrión S, Domènech E, Antonio Arévalo J, Mañosa M, Cabré E, Luis Cabriada J, Àngel Gassull M. Mononucleosis infecciosa en pacientes con enfermedad inflamatoria intestinal en tratamiento con azatioprina. Gastroenterología y Hepatología 2008;31:289-92. [DOI: 10.1157/13119881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
261 Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. [PMID: 16530505 DOI: 10.1053/j.gastro.2005.12.019] [Cited by in Crossref: 580] [Cited by in F6Publishing: 525] [Article Influence: 38.7] [Reference Citation Analysis]
262 Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58. [PMID: 23055441 DOI: 10.1002/art.37740] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
263 Gomollón F, López SG. Are we giving azathioprine too much time? World J Gastroenterol 2008; 14(36): 5519-5522 [PMID: 18810769 DOI: 10.3748/wjg.14.5519] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
264 Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23:395-399. [PMID: 17545775 DOI: 10.1097/mog.0b013e32815b601b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
265 Kim JH, Kim JW. Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2017;70:162. [DOI: 10.4166/kjg.2017.70.4.162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
267 Shergill AK, Terdiman JP. Controversies in the treatment of Crohn’s disease: The case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14(17): 2670-2677 [PMID: 18461652 DOI: 10.3748/wjg.14.2670] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
268 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 15.6] [Reference Citation Analysis]
269 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
270 Kelsen JR, Sullivan KE. Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep 2017;17:57. [PMID: 28755025 DOI: 10.1007/s11882-017-0724-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
271 Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306-1321. [PMID: 23470503 DOI: 10.1097/mib.0b013e3182807618] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
272 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
273 Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis. 2012;18:1608-1616. [PMID: 21905173 DOI: 10.1002/ibd.21904] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
274 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
275 Lo B, Zhao M, Vind I, Burisch J. The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. Clinical Gastroenterology and Hepatology 2021;19:1117-1138.e19. [DOI: 10.1016/j.cgh.2020.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
276 Jung YS, Park DI, Moon CM, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Radiation exposure from abdominal imaging studies in patients with intestinal Behçet disease. Gut Liver 2014;8:380-7. [PMID: 25071902 DOI: 10.5009/gnl.2014.8.4.380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
277 Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625. [PMID: 19837455 DOI: 10.1016/s0140-6736(09)61302-7] [Cited by in Crossref: 686] [Cited by in F6Publishing: 199] [Article Influence: 57.2] [Reference Citation Analysis]
278 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.6] [Reference Citation Analysis]
279 Pereira C, Coelho R, Grácio D, Dias C, Silva M, Peixoto A, Lopes P, Costa C, Teixeira JP, Macedo G, Magro F. DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. J Crohns Colitis 2016;10:1316-23. [PMID: 27095753 DOI: 10.1093/ecco-jcc/jjw088] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
280 Verwijst J, Westerberg E, Punga AR. Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study. Eur J Neurol 2021;28:1706-15. [PMID: 33427389 DOI: 10.1111/ene.14730] [Reference Citation Analysis]
281 El Mourabet M, Hashash JG, Sun NH, Issa M, Katz JA, Regueiro M, Barrie AM 3rd, Baidoo L, Schwartz MB, Swoger JM, Levesque MC, Binion DG. Clinical course of Crohn's disease following treatment of lymphoma. Inflamm Bowel Dis 2011;17:1265-9. [PMID: 21351199 DOI: 10.1002/ibd.21487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
282 Cappello M, Bravatà I, Cocorullo G, Cacciatore M, Florena AM. Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression. Am J Gastroenterol 2011;106:1863-5. [PMID: 21979217 DOI: 10.1038/ajg.2011.204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
283 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
284 Aloi M, Di Nardo G, Conte F, Mazzeo L, Cavallari N, Nuti F, Cucchiara S, Stronati L. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre: Methotrexate in paediatric ulcerative colitis. Alimentary Pharmacology & Therapeutics 2010;32:1017-22. [DOI: 10.1111/j.1365-2036.2010.04433.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
285 Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6:65-77. [PMID: 25729557 DOI: 10.1177/2040622314563929] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
286 Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin’s lymphoma in a North American population: population-based study. Am J Gastroenterol. 2008;103:1762-1769. [PMID: 18557717 DOI: 10.1111/j.1572-0241.2008.01794.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
287 Marcelis L, Berghen C, De Zutter A, Biesemans P, Vandenberghe P, Verhoef G, Gheysens O, Sagaert X, Dierickx D, Tousseyn T. Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases. Mod Pathol 2018;31:1457-69. [PMID: 29765143 DOI: 10.1038/s41379-018-0054-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Moran G, Dillon J, Green J. Crohn’s disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree. Inflamm Bowel Dis. 2009;15:1281-1282. [PMID: 19067412 DOI: 10.1002/ibd.20802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
289 Rosh JR. Use of biologic agents in pediatric inflammatory bowel disease. Current Opinion in Pediatrics 2009;21:646-50. [DOI: 10.1097/mop.0b013e32832ff22c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
290 Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: A retrospective review. Journal of the American Academy of Dermatology 2015;73:439-43. [DOI: 10.1016/j.jaad.2015.05.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
291 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 725] [Article Influence: 75.1] [Reference Citation Analysis]
292 Ruud TE, Gundersen Y, Krohn CD, Sveen O, Aasen AO. Effects of Infliximab and Hydrocortisone on In Vitro Cytokine Responses after Stimulation with Lipopolysaccharide. Surgical Infections 2013;14:30-4. [DOI: 10.1089/sur.2011.093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
293 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
294 Schulze T, Lüdtke A, Rahlff I, Tunn PU, Hohenberger P. Salmonella osteomyelitis in an immunocompromized patient presenting as a primary lymphoma of the bone. Int J Infect Dis 2009;13:e67-70. [PMID: 18845462 DOI: 10.1016/j.ijid.2008.06.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
295 Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571-583. [PMID: 20213337 DOI: 10.1007/s00535-010-0219-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 117] [Article Influence: 10.5] [Reference Citation Analysis]
296 Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM; European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology; Hepatology; and Nutrition. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340-361. [PMID: 22773060 DOI: 10.1097/mpg.0b013e3182662233] [Cited by in Crossref: 251] [Cited by in F6Publishing: 67] [Article Influence: 31.4] [Reference Citation Analysis]
297 Chiorean MV, Pokhrel B, Adabala J, Helper DJ, Johnson CS, Juliar B. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci 2011;56:1489-95. [PMID: 20953706 DOI: 10.1007/s10620-010-1430-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
298 Markowitz J. The Natural History of Pediatric Crohn Disease. In: Mamula P, Markowitz JE, Baldassano RN, editors. Pediatric Inflammatory Bowel Disease. Boston: Springer US; 2008. pp. 67-74. [DOI: 10.1007/978-0-387-73481-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
299 Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stüve O, Hemmer B, Berthele A. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009;66:403-6. [DOI: 10.1002/ana.21782] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
300 Patil SA, Rustgi A, Quezada SM, Flasar MH, Vandermeer F, Cross RK. Anti-TNF Therapy Is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2013;19:92-8. [DOI: 10.1002/ibd.22982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
301 Hullah EA, Blaker PA, Marinaki AM, Escudier MP, Sanderson JD. A practical guide to the use of thiopurines in oral medicine. J Oral Pathol Med 2015;44:761-8. [PMID: 25529219 DOI: 10.1111/jop.12274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
302 Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol 2008; 14(25): 3937-3947 [PMID: 18609676 DOI: 10.3748/wjg.14.3937] [Cited by in CrossRef: 231] [Cited by in F6Publishing: 212] [Article Influence: 17.8] [Reference Citation Analysis]
303 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 10.4] [Reference Citation Analysis]
304 Velayos F, Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery? Clin Gastroenterol Hepatol 2007;5:668-71. [PMID: 17544992 DOI: 10.1016/j.cgh.2007.03.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
305 Barzilai M, Polliack A, Avivi I, Herishanu Y, Ram R, Tang C, Perry C, Sarid N. Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. Leukemia Research 2018;71:1-5. [DOI: 10.1016/j.leukres.2018.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
306 Ross S, Rajwal SK, Sugarman I, Picton S, Devlin J, Davison S, McClean P. Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr 2010;51:229-31. [PMID: 20512052 DOI: 10.1097/MPG.0b013e3181d893c6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
307 Tao JH, Duan JA, Jiang S, Guo JM, Qian YY, Qian DW. Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1029-1030:88-94. [PMID: 27428450 DOI: 10.1016/j.jchromb.2016.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
308 Loganathan S, Zaitoun A, Charlton C. Lymphoma With Central Nervous System Involvement in a Young Patient With Crohn Disease Treated With Azathioprine. Journal of Pediatric Gastroenterology & Nutrition 2010;51:790-2. [DOI: 10.1097/mpg.0b013e3181edf33f] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
309 Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma. 2007;48:1410-1413. [PMID: 17613771 DOI: 10.1080/10428190701345433] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
310 Fuchs Y, Markowitz J, Weinstein T, Kohn N, Choi-Rosen J, Levine J. Pediatric inflammatory bowel disease and imaging-related radiation: are we increasing the likelihood of malignancy? J Pediatr Gastroenterol Nutr. 2011;52:280-285. [PMID: 21297507 DOI: 10.1097/mpg.0b013e3181f57177] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
311 Wadhwa V, Lopez R, Shen B. Crohnʼs Disease Is Associated with the Risk for Thyroid Cancer: . Inflammatory Bowel Diseases 2016;22:2902-6. [DOI: 10.1097/mib.0000000000000963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
312 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
313 Van Domselaar M, López San Román A, Bastos Oreiro M, Garrido Gómez E. [Lymphoproliferative disorders in an inflammatory bowel disease unit]. Gastroenterol Hepatol 2010;33:12-6. [PMID: 19889478 DOI: 10.1016/j.gastrohep.2009.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
314 Ormerod C, Sarkar S, Woodcock B, White D, Lal S. Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease. BMJ Case Rep 2010;2010:bcr0320102809. [PMID: 22778189 DOI: 10.1136/bcr.03.2010.2809] [Reference Citation Analysis]
315 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
316 Yuan B, O'Connor TR, Wang Y. 6-Thioguanine and S⁶-methylthioguanine are mutagenic in human cells. ACS Chem Biol 2010;5:1021-7. [PMID: 20806951 DOI: 10.1021/cb100214b] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
317 Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, Horwitz SM. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13:8-14. [PMID: 23107915 DOI: 10.1016/j.clml.2012.09.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
318 Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. Eur J Haematol 2015;94:206-18. [PMID: 25154298 DOI: 10.1111/ejh.12439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
319 Lee LY, Namuduri R, Chan MMF, Quek JKS, Koh MJ. Epstein-Barr virus positive diffuse large B-cell lymphoma presenting with vaginal sloughing and ulcerated skin nodule. J Cutan Pathol 2018;45:162-6. [PMID: 29086996 DOI: 10.1111/cup.13074] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
320 Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51. [PMID: 21963958 DOI: 10.1016/j.cgh.2011.09.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
321 Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378-389. [PMID: 18200660 DOI: 10.3748/wjg.v14.i3.378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Levhar N, Ungar B, Kopylov U, Fudim E, Yavzori M, Picard O, Amariglio N, Chowers Y, Shemer-Avni Y, Mao R, Chen MH, Ye Z, Eliakim R, Ben-Horin S. Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1330-9. [PMID: 32322878 DOI: 10.1093/ibd/izaa065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
323 Beaugerie L, Rahier JF, Kirchgesner J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 1324-1335. e2. [PMID: 32059920 DOI: 10.1016/j.cgh.2020.02.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
324 Chevaux J, Peyrin-biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease: . Inflammatory Bowel Diseases 2011;17:1428-35. [DOI: 10.1002/ibd.21494] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
325 Markowitz J. Current treatment of inflammatory bowel disease in children. Digestive and Liver Disease 2008;40:16-21. [DOI: 10.1016/j.dld.2007.07.167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
326 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
327 Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. [PMID: 17480018 DOI: 10.1002/ibd.20169] [Cited by in Crossref: 169] [Cited by in F6Publishing: 145] [Article Influence: 12.1] [Reference Citation Analysis]
328 Rashidi A, Lee ME, Fisher SI. Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy. Int J Hematol 2012;95:592-4. [PMID: 22527855 DOI: 10.1007/s12185-012-1081-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
329 Krishnan M, Lunning M. Hepatosplenic γ-δ T-Cell Lymphoma: Who Is on Your Speed Dial? J Oncol Pract 2019;15:307-12. [PMID: 31185190 DOI: 10.1200/JOP.18.00594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
330 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
331 Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. Dig Liver Dis. 2013;45:269-276. [PMID: 23010518 DOI: 10.1016/j.dld.2012.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
332 Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, Chen L, Xie F, Curtis JR, Lewis JD. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Clin Gastroenterol Hepatol. 2015;13:1293-1301.e5; quiz e70, e72. [PMID: 25724699 DOI: 10.1016/j.cgh.2015.02.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
333 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
334 Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41.e1. [PMID: 20888436 DOI: 10.1016/j.cgh.2010.09.016] [Cited by in Crossref: 305] [Cited by in F6Publishing: 244] [Article Influence: 27.7] [Reference Citation Analysis]
335 Mardini HE, Schwartz DA. Treatment of perianal fistula and abscess: Crohn’s and non-Crohn’s. Curr Treat Options Gastro 2007;10:211-20. [DOI: 10.1007/s11938-007-0014-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
336 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
337 Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 2013;12:98. [PMID: 23987103 DOI: 10.1186/1476-4598-12-98] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
338 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
339 Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2014;20:2132-41. [DOI: 10.1097/mib.0000000000000218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
340 Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Golovics PA, Vegh Z, Mandel M, Horvath A, Szathmari M, Kiss LS, Lakatos L. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91. [PMID: 22766526 DOI: 10.1016/j.crohns.2012.06.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
341 Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012;18:838-843. [PMID: 21887728 DOI: 10.1002/ibd.21844] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
342 Nieminen U, Färkkilä M. Malignancies in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2014;50:81-9. [DOI: 10.3109/00365521.2014.992041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
343 Chaparro M, Ordás I, Cabré E, Garcia-sanchez V, Bastida G, Peñalva M, Gomollón F, García-planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients. Inflammatory Bowel Diseases 2013;19:1404-10. [DOI: 10.1097/mib.0b013e318281f28f] [Cited by in Crossref: 178] [Cited by in F6Publishing: 62] [Article Influence: 22.3] [Reference Citation Analysis]
344 Zheng S, Xu H, Ouyang Q, Xue L, Zhang Y, Cui D. A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn's disease. Chin J Cancer Res 2013;25:119-23. [PMID: 23372350 DOI: 10.3978/j.issn.1000-9604.2012.12.06] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
345 Click RE. Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases. Virulence 2011;2:131-43. [PMID: 21460639 DOI: 10.4161/viru.2.2.15647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
346 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
347 Subramanian V, Logan RF. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2011;25:593-606. [PMID: 22122774 DOI: 10.1016/j.bpg.2011.09.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
348 Hujoel IA, Rubio-Tapia A, Dao LN, Porrata LF, Kane SV. Epstein-Barr Virus-Positive Mucocutaneous Ulcer in an Immunosuppressed Patient. ACG Case Rep J 2018;5:e32. [PMID: 29721514 DOI: 10.14309/crj.2018.32] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
349 Annaházi A, Molnár T. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract 2015;2015:832395. [PMID: 26199624 DOI: 10.1155/2015/832395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
350 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 117] [Article Influence: 13.3] [Reference Citation Analysis]
351 Cassinotti A, Massari A, Ferrara E, Greco S, Bosani M, Ardizzone S, Bianchi Porro G. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol. 2007;63:875-878. [PMID: 17598094 DOI: 10.1007/s00228-007-0328-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
352 Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S; New York Crohn's and Colitis Organization. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016;14:58-64. [PMID: 26247164 DOI: 10.1016/j.cgh.2015.07.037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
353 Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res 2021;19:419-29. [PMID: 33166442 DOI: 10.5217/ir.2020.00033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Helper DJ. Medical management of Crohn's disease: A guide for radiologists. European Journal of Radiology 2009;69:371-4. [DOI: 10.1016/j.ejrad.2008.11.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
355 Lakatos L, Lakatos PL. [Medical therapy of inflammatory bowel diseases: ulcerative colitis]. Orv Hetil 2007;148:1163-70. [PMID: 17573252 DOI: 10.1556/OH.2007.28063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
356 Wilson JC, Furlano RI, Jick SS, Meier CR. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol 2016;51:1050-62. [PMID: 27056729 DOI: 10.1007/s00535-016-1199-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
357 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
358 Riello L, Talbotec C, Garnier-Lengliné H, Pigneur B, Svahn J, Canioni D, Goulet O, Schmitz J, Ruemmele FM. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138-2143. [PMID: 21910176 DOI: 10.1002/ibd.21612] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
359 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Alexander H, Patton T, Jabbar-Lopez ZK, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? F1000Res 2019;8:F1000 Faculty Rev-132. [PMID: 30774935 DOI: 10.12688/f1000research.17039.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
361 Leedham SJ, Jankowski JA, Wright NA, Tomlinson IPM. Genetics of inflammatory bowel disease and associated cancers. Curr colorectal cancer rep 2006;2:191-9. [DOI: 10.1007/s11888-006-0022-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
362 Kaplan GG. Administrative Database Studies in IBD: A Cautionary Tale. American Journal of Gastroenterology 2010;105:1808-10. [DOI: 10.1038/ajg.2010.232] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
363 Park SK, Ye BD, Lee C, Im JP, Kim YH, Kim SO, Byeon JS, Myung SJ, Yang SK, Kim JH. Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study. J Clin Gastroenterol 2015;49:e11-6. [PMID: 24705089 DOI: 10.1097/MCG.0000000000000129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
364 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
365 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
366 Biswas A, Mukherjee A. Therapy of NMO spectrum disorders. Ann Indian Acad Neurol 2015;18:S16-23. [PMID: 26538843 DOI: 10.4103/0972-2327.164818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
367 Miwa W, Hiratsuka T, Tei S, Sato K, Yo K. Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis. Clin J Gastroenterol 2019;12:160-5. [PMID: 30238285 DOI: 10.1007/s12328-018-0907-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
368 Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847-58.e4; quiz e48-50. [PMID: 24879926 DOI: 10.1016/j.cgh.2014.05.015] [Cited by in Crossref: 212] [Cited by in F6Publishing: 171] [Article Influence: 30.3] [Reference Citation Analysis]
369 Ribeiro TCDR, Chebli LA, Gaburri PD, Chebli JMF. Azathioprine in ulcerative colitis: Why, when, how and how long to use it. Drug Dev Res 2011;72:733-8. [DOI: 10.1002/ddr.20481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
370 Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis: . Journal of Clinical Gastroenterology 2006;40:669-77. [DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
371 Aggarwal D, Limdi JK. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2015;27:13-9. [PMID: 25341058 DOI: 10.1097/MEG.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
372 Steckley JL, Tartaglia MC, Reddy H, Huang S, Hammond R, Hyson C. Systemic lupus erythematosus and right leg weakness. Can J Neurol Sci 2009;36:98-101. [PMID: 19294898 DOI: 10.1017/s0317167100006405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
373 Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735-44. [PMID: 24788825 DOI: 10.1002/pds.3621] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
374 Murata M, Sugimoto M, Yokota Y, Ban H, Inatomi O, Bamba S, Kushima R, Andoh A. Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis. World J Gastroenterol 2016; 22(47): 10471-10476 [PMID: 28058029 DOI: 10.3748/wjg.v22.i47.10471] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
375 Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD006320. [PMID: 19160277 DOI: 10.1002/14651858.cd006320.pub3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
376 Humphreys MR, Cino M, Quirt I, Barth D, Kukreti V. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha. Leuk Lymphoma. 2008;49:1420-1423. [PMID: 18452073 DOI: 10.1080/10428190802087488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
377 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
378 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 10.5] [Reference Citation Analysis]
379 Søgaard KK, Cronin-Fenton DP, Pedersen L, Sørensen HT, Lash TL. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2008;14:519-525. [PMID: 18069672 DOI: 10.1002/ibd.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
380 Jung YS, Park DI, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Chan Huh K, Jung SA, Yoon SM. Quantifying exposure to diagnostic radiation and factors associated with exposure to high levels of radiation in Korean patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1852-1857. [PMID: 23702806 DOI: 10.1097/mib.0b013e31828c844f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
381 Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51. [PMID: 28839543 DOI: 10.1136/fg.2009.000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
382 Yabe M, Medeiros LJ, Daneshbod Y, Davanlou M, Bueso-Ramos CE, Moran EJ, Young KH, Miranda RN. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. Ann Diagn Pathol 2017;26:16-22. [PMID: 28038706 DOI: 10.1016/j.anndiagpath.2016.10.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
383 Perkovic S, Basic-Kinda S, Gasparovic V, Krznaric Z, Babel J, Ilic I, Aurer I, Batinic D. Epstein-Barr virus-negative aggressive natural killer-cell leukaemia with high P-glycoprotein activity and phosphorylated extracellular signal-regulated protein kinases 1 and 2. Hematol Rep 2012;4:e16. [PMID: 23087805 DOI: 10.4081/hr.2012.e16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
384 Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007-1015.e3. [PMID: 23891975 DOI: 10.1053/j.gastro.2013.07.035] [Cited by in Crossref: 144] [Cited by in F6Publishing: 120] [Article Influence: 18.0] [Reference Citation Analysis]
385 Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2013;10:413-422. [PMID: 23648935 DOI: 10.1038/nrgastro.2013.69] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
386 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 468] [Article Influence: 82.9] [Reference Citation Analysis]
387 Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71. [PMID: 17602971 DOI: 10.1053/j.sempedsurg.2007.04.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
388 Jess T. Thiopurines for Inflammatory Bowel Disease: Time to Engage With Dermatologists? Gastroenterology 2011;141:1549-51. [DOI: 10.1053/j.gastro.2011.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
389 Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
390 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
391 Zaiatz Bittencourt V, Jones F, Doherty G, Ryan EJ. Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab024. [PMID: 33693743 DOI: 10.1093/ibd/izab024] [Reference Citation Analysis]
392 Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis 2017;11:571-7. [PMID: 28453756 DOI: 10.1093/ecco-jcc/jjw193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
393 Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia: Safety of anti TNF treatment in IBD. Internal Medicine Journal 2010;40:139-49. [DOI: 10.1111/j.1445-5994.2009.02122.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
394 Brambilla M, De Mauri A, Lizio D, Leva L, Carriero A, Carpeggiani C, Picano E. Cumulative radiation dose estimates from medical imaging in paediatric patients with non-oncologic chronic illnesses. A systematic review. Physica Medica 2014;30:403-12. [DOI: 10.1016/j.ejmp.2013.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
395 Kim MJ, Choe YH. Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2013;16:65-70. [PMID: 24010109 DOI: 10.5223/pghn.2013.16.2.65] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
396 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
397 Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32:327-339. [PMID: 19820441 DOI: 10.1097/sga.0b013e3181bb1484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
398 Dasari BV, McBrearty A, Gardiner K. Immunosuppression in patients with Crohn's disease and neoplasia: an ongoing clinical dilemma. Dis Colon Rectum 2012;55:1008-11. [PMID: 22874610 DOI: 10.1097/DCR.0b013e31825d9269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
399 Owen CE, Callen JP, Bahrami S. Cutaneous lymphoproliferative disorder complicating infectious mononucleosis in an immunosuppressed patient. Pediatr Dermatol 2011;28:149-55. [PMID: 20497356 DOI: 10.1111/j.1525-1470.2010.01087.x] [Reference Citation Analysis]
400 Bermejo F, Gisbert JP. Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Ther Adv Chronic Dis 2010;1:107-14. [PMID: 23251733 DOI: 10.1177/2040622310374897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
401 Beaugerie L. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? Dig Dis. 2012;30:415-419. [PMID: 22796808 DOI: 10.1159/000338144] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
402 Park KC, Ju DU, Heo SW, Ryu JI, Cho JY, Kim EJ, Oh HK, Kim EY. [A case of squamous cell carcinoma of the breast in a patient with Crohn's disease taking azathioprine]. Korean J Gastroenterol 2012;60:373-6. [PMID: 23242021 DOI: 10.4166/kjg.2012.60.6.373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
403 Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn‘s disease. Curr Gastroenterol Rep. 2011;13:465-474. [PMID: 21792543 DOI: 10.1007/s11894-011-0220-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
404 Ishida M, Naka S, Shiomi H, Tsujikawa T, Andoh A, Nakahara T, Saito Y, Kurumi Y, Takikita-Suzuki M, Kojima F, Hotta M, Tani T, Fujiyama Y, Okabe H. Hepatocellular carcinoma occurring in a Crohn’s disease patient. World J Gastroenterol 2010; 16(25): 3215-3218 [PMID: 20593510 DOI: 10.3748/wjg.v16.i25.3215] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
405 Sato K, Suga T, Hirayama A, Daikuhara S, Uehara T, Tanaka E. Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. Clin J Gastroenterol 2020;13:1-5. [PMID: 31350718 DOI: 10.1007/s12328-019-01026-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
406 Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296-1305. [PMID: 23514635 DOI: 10.1093/aje/kws375] [Cited by in Crossref: 124] [Cited by in F6Publishing: 106] [Article Influence: 15.5] [Reference Citation Analysis]
407 Scribano ML. Adverse events of IBD therapies: . Inflammatory Bowel Diseases 2008;14:S210-1. [DOI: 10.1002/ibd.20702] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
408 Fidalgo C, Ferreira S, Rosa I, de Ferro SM, Pereira AD. Familial adenomatous polyposis and Crohn's disease in one patient: dilemmas and concerns. Case Rep Gastroenterol 2013;7:358-62. [PMID: 24019770 DOI: 10.1159/000354972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
409 Courby S, Fabre B, Salameire D, Gaulard P, Hincky-Vitrat V, Gressin R, Bonaz B, Epaulard O. Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab. Leuk Lymphoma 2010;51:174-7. [PMID: 20001240 DOI: 10.3109/10428190903402029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
410 Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, Novak K, Kaplan GG, Iacucci M, Seow C. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002-1024. [PMID: 24099467 DOI: 10.1111/apt.12491] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
411 Nguyen T, Vacek PM, O’Neill P, Colletti RB, Finette BA. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 2009;69:7004-7012. [PMID: 19706768 DOI: 10.1158/0008-5472.can-09-0451] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
412 Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol 2013; 19(11): 1699-1706 [PMID: 23555158 DOI: 10.3748/wjg.v19.i11.1699] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
413 罗凤燕, 白爱平. 硫唑嘌呤治疗炎症性肠病诱发淋巴瘤. 世界华人消化杂志 2013; 21(22): 2121-2127 [DOI: 10.11569/wcjd.v21.i22.2121] [Reference Citation Analysis]
414 Manresa MC, Taylor CT. Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function. Cell Mol Gastroenterol Hepatol 2017;3:303-15. [PMID: 28462372 DOI: 10.1016/j.jcmgh.2017.02.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
415 Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198. [PMID: 17521218 DOI: 10.2165/00003495-200767080-00006] [Cited by in Crossref: 244] [Cited by in F6Publishing: 209] [Article Influence: 17.4] [Reference Citation Analysis]
416 Xu S, Chen H, Zu X, Hao X, Feng R, Zhang S, Chen B, Zeng Z, Chen M, Ye Z, He Y. Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. Therap Adv Gastroenterol 2020;13:1756284820930124. [PMID: 32913442 DOI: 10.1177/1756284820930124] [Reference Citation Analysis]
417 Anumakonda V, Hayee B, Chung-Faye G. Remission and relapse of Crohn’s disease following autologous haematopoietic stem cell transplantation for non-Hodgkin’s lymphoma. Gut. 2007;56:1325. [PMID: 17438083 DOI: 10.1136/gut.2006.111377] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
418 Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146-53. [PMID: 22031357 DOI: 10.1038/ajg.2011.283] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 13.2] [Reference Citation Analysis]
419 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
420 Lourensz K, Jones I. Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: A case report. Int J Surg Case Rep 2015;10:73-5. [PMID: 25805613 DOI: 10.1016/j.ijscr.2015.03.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
421 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
422 Sultan K, Korelitz BI, Present D, Katz S, Sunday S, Shapira I. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1855-8. [PMID: 22241664 DOI: 10.1002/ibd.22866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
423 N’guyen Y, Andreoletti L, Patey M, Lecoq-Lafon C, Cornillet P, Léon A, Jaussaud R, Fieschi C, Strady C. Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn’s disease. J Clin Microbiol. 2009;47:1252-1254. [PMID: 19193838 DOI: 10.1128/jcm.02052-08] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
424 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
425 Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 2012;6:125-34. [PMID: 22740771 DOI: 10.2147/BTT.S31833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
426 Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1308-1319. [PMID: 19434735 DOI: 10.1002/ibd.20956] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 7.5] [Reference Citation Analysis]
427 Feng D, Yang Y, Wang Z, Wei W, Li L. Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies. Transl Androl Urol 2021;10:1332-41. [PMID: 33850767 DOI: 10.21037/tau-20-1358] [Reference Citation Analysis]
428 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
429 Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M; Members of the Ministry of Health and Welfare of Japan’s Inflammatory Bowel Diseases Study Group. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol 2014;49:1299-306. [PMID: 23955181 DOI: 10.1007/s00535-013-0873-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
430 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 21.9] [Reference Citation Analysis]
431 Gordon J, Ramaswami A, Beuttler M, Jossen J, Pittman N, Lai J, Dunkin D, Benkov K, Dubinsky M. EBV Status and Thiopurine Use in Pediatric IBD. J Pediatr Gastroenterol Nutr 2016;62:711-4. [PMID: 26655944 DOI: 10.1097/MPG.0000000000001077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 7.3] [Reference Citation Analysis]
432 Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut 2014;63:1695-9. [PMID: 24943205 DOI: 10.1136/gutjnl-2013-306711] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
433 Ayyala US, Padilla ML. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options Gastroenterol. 2006;9:475-483. [PMID: 17081481 DOI: 10.1007/s11938-006-0004-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
434 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
435 Colombel JF, Peyrin-Biroulet L. Natalizumab: a promising treatment for Crohn's disease. Expert Rev Clin Immunol 2006;2:677-89. [PMID: 20477624 DOI: 10.1586/1744666X.2.5.677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 Hosni-Ahmed A, Barnes JD, Wan J, Jones TS. Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS One 2011;6:e29163. [PMID: 22216194 DOI: 10.1371/journal.pone.0029163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
437 Swanson G, Behara R, Braun R, Keshavarzian A. Diagnostic medical radiation in inflammatory bowel disease: how to limit risk and maximize benefit. Inflamm Bowel Dis. 2013;19:2501-2508. [PMID: 23792551 DOI: 10.1097/mib.0b013e31828dc6b6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
438 Zhang Z, Wang M, Xu L, Jiang B, Jin T, Shi T, Xu B. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis. J Clin Neurosci 2021;88:70-4. [PMID: 33992207 DOI: 10.1016/j.jocn.2021.03.015] [Reference Citation Analysis]
439 Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, Teresa-Galván JD, Redondo-Cerezo E. Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. World J Gastroenterol 2013; 19(30): 4877-4886 [PMID: 23946592 DOI: 10.3748/wjg.v19.i30.4877] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
440 Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299-1307. [PMID: 17600819 DOI: 10.1002/ibd.20211] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
441 Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD000067. [PMID: 19160175 DOI: 10.1002/14651858.cd000067.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 62] [Article Influence: 2.6] [Reference Citation Analysis]
442 Chatu S, Poullis A, Holmes R, Greenhalgh R, Pollok RC. Temporal trends in imaging and associated radiation exposure in inflammatory bowel disease. Int J Clin Pract. 2013;67:1057-1065. [PMID: 24073979 DOI: 10.1111/ijcp.12187] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
443 Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 6.0] [Reference Citation Analysis]
444 Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, Masliah-Planchon J, Billot K, Canioni D, Frange P. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood. 2013;122:3713-3722. [PMID: 24089328 DOI: 10.1182/blood-2013-06-508267] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
445 Shen X, Wan Q, Zhao R, Wu Y, Wang Y, Cui Y, Su X, Wu X. Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies. Dig Liver Dis 2021;53:809-16. [PMID: 33551353 DOI: 10.1016/j.dld.2021.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
446 Israeli E, Ying S, Henderson B, Mottola J, Strome T, Bernstein CN. The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:513-21. [DOI: 10.1111/apt.12410] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
447 McGovern DP, Jewell DP. Risks and benefits of azathioprine therapy. Gut 2005;54:1055-9. [PMID: 16009676 DOI: 10.1136/gut.2004.053231] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
448 Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012;6:578-587. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
449 von der Brelie C, Kuchelmeister K, Stein H, Boström A. Coexistence of spinal schwannoma with unusual malignant peripheral T-cell lymphoma within a lumbar spine lesion. Acta Neurochir (Wien) 2011;153:1723-4. [PMID: 21638142 DOI: 10.1007/s00701-011-1058-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
450 Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:942-951. [PMID: 25687629 DOI: 10.3109/00365521.2015.1014407] [Cited by in Crossref: 186] [Cited by in F6Publishing: 162] [Article Influence: 31.0] [Reference Citation Analysis]
451 Holubar SD, Dozois EJ, Loftus EV Jr, Teh SH, Benavente LA, Harmsen WS, Wolff BG, Cima RR, Larson DW. Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era. Inflamm Bowel Dis 2011;17:1557-63. [PMID: 21674712 DOI: 10.1002/ibd.21516] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
452 Hradsky O, Copova I, Zarubova K, Durilova M, Nevoral J, Maminak M, Hubacek P, Bronsky J. Seroprevalence of Epstein–Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. Dig Dis Sci 2015;60:3399-407. [DOI: 10.1007/s10620-015-3764-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
453 Kwakernaak AJ, Hazenberg MD, Roelofs JJ, van Noesel CJ, van Oers MH, van Tellingen A. Precursor T-lymphoblastic lymphoma presenting as primary renal lymphoma with acute renal failure. NDT Plus 2011;4:289-91. [PMID: 25984171 DOI: 10.1093/ndtplus/sfr079] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
454 Nagai T, Okamura T, Katayama K, Chaya R, Tanaka Y, Kobayashi D, Kobayashi T, Akita H, Yasui T. Primary diffuse large B-cell lymphoma of the ileal conduit created after radical cystectomy. IJU Case Rep 2018;1:22-4. [PMID: 32743358 DOI: 10.1002/iju5.12022] [Reference Citation Analysis]
455 Gay ND, Chen A, Okada CY. Colorectal Lymphoma: A Review. Clin Colon Rectal Surg 2018;31:309-16. [PMID: 30186053 DOI: 10.1055/s-0038-1642048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
456 O'Connor A, Qasim A, O'Moráin CA. The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis 2010;1:7-16. [PMID: 23251725 DOI: 10.1177/2040622310368736] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
457 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
458 Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, Rosh JR, Carvalho R, Grossman AB, Cabrera J, Pfefferkorn MD, Rick J, Leleiko NS, Hitch MC, Oliva-hemker M, Saeed SA, Kappelman M, Markowitz J, Keljo DJ. Retrospective Cohort Study of Methotrexate Use in the Treatment of Pediatric Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:1341-5. [DOI: 10.1097/mib.0000000000000102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
459 Fernandez Salazar L, Rojo S, De Lejarazu RO, Castro E, Higuera E, González JM. No increase in Epstein-Barr virus viral load in a group of 30 asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2013;108:1933-1935. [PMID: 24300873 DOI: 10.1038/ajg.2013.250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
460 Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, Mcdonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A. Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin. Clinical Gastroenterology and Hepatology 2008;6:1370-7. [DOI: 10.1016/j.cgh.2008.06.007] [Cited by in Crossref: 203] [Cited by in F6Publishing: 195] [Article Influence: 15.6] [Reference Citation Analysis]
461 Connors W, Griffiths C, Patel J, Belletrutti PJ. Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. BMC Gastroenterol 2014;14:127. [PMID: 25022612 DOI: 10.1186/1471-230X-14-127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
462 Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis. World J Gastroenterol 2015; 21(15): 4744-4749 [PMID: 25914486 DOI: 10.3748/wjg.v21.i15.4744] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
463 Malik TA. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. Surg Clin North Am. 2015;95:1105-1122, v. [PMID: 26596917 DOI: 10.1016/j.suc.2015.07.006] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
464 Rosen DJ, Dubinsky MC. The Evolving Role of Thiopurines for Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:234-40. [PMID: 26355469 DOI: 10.1097/MIB.0000000000000583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
465 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
466 Sabbah M, Ben Farhat F, Bellil N, Khanchel F, Ouakaa A, Gargouri D. An unusual case of diffuse large B-cell lymphoma complicating a Crohn's disease. Clin Case Rep 2020;8:3062-5. [PMID: 33363880 DOI: 10.1002/ccr3.3364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
467 Ikarashi S, Tsuchiya A, Kawata Y, Kojima Y, Watanabe T, Takeuchi S, Igarashi K, Ideta-Otsuka M, Oki K, Takamura M, Terai S. Effects of Human Adipose Tissue-Derived and Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in a Dextran Sulfate Sodium-Induced Mouse Model. Biores Open Access 2019;8:185-99. [PMID: 31720090 DOI: 10.1089/biores.2019.0022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
468 Adam L, Phulukdaree A, Soma P. Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine. Biomed Pharmacother 2018;100:8-14. [PMID: 29421584 DOI: 10.1016/j.biopha.2018.01.152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
469 Gong J, Zhu L, Guo Z, Li Y, Zhu W, Li N, Li J. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One. 2013;8:e81487. [PMID: 24312308 DOI: 10.1371/journal.pone.0081487] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
470 Yasuda T, Takagi T, Asai J, Katoh N, Kuroda J, Kuwahara Y, Morinaga Y, Konishi E, Uchiyama K, Naito Y, Itoh Y. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. Clin J Gastroenterol 2021;14:170-5. [PMID: 33219936 DOI: 10.1007/s12328-020-01277-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
471 Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729. [PMID: 16918876 DOI: 10.1111/j.1365-2036.2006.02980.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 7.2] [Reference Citation Analysis]
472 Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
473 Goel RM, Blaker P, Mentzer A, Fong SC, Marinaki AM, Sanderson JD. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6:138-146. [PMID: 25954498 DOI: 10.1177/2040622315579063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
474 Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
475 McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM, Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ. Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease. J Clin Invest 2015;125:3215-25. [PMID: 26168223 DOI: 10.1172/JCI80840] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
476 Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, Fornarini GS, Riso D, Campieri M, Rizzello F. Role of conventional therapies in the era of biological treatment in Crohn’s disease. World J Gastroenterol 2011; 17(14): 1797-1806 [PMID: 21528051 DOI: 10.3748/wjg.v17.i14.1797] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
477 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]